Bulletin
Investor Alert

New York Markets Close in:

Dicerna Pharmaceuticals Inc.

NAS: DRNA

GO
/marketstate/country/us

Market open

 --Real time quotes

Sep 18, 2020, 2:08 p.m.

/zigman2/quotes/203776010/composite

$

19.62

Change

+0.01 +0.08%

Volume

Volume 340,532

Real time quotes

/zigman2/quotes/203776010/composite

Previous close

$ 19.60

$ 19.62

Change

+0.01 +0.08%

Day low

Day high

$19.41

$20.05

Open

52 week low

52 week high

$11.75

$27.68

Open

Annual Financials for Dicerna Pharmaceuticals Inc.

Fiscal year is January-December. All values USD millions. 20152016201720182019 5-year trend
Sales/Revenue 184,000295,0001.03M6.18M23.9M
Cost of Goods Sold (COGS) incl. D&A -----
COGS excluding D&A -----
Depreciation & Amortization Expense 727,000840,000778,000774,0001.25M
Depreciation 727,000840,000778,000774,0001.25M
Amortization of Intangibles -----
Gross Income -----
20152016201720182019 5-year trend
SG&A Expense 62.48M59.2M51.95M66.62M150.84M
Research & Development 43.97M41.69M35.89M45.71M108.09M
Other SG&A 18.51M17.51M16.06M20.91M42.75M
Other Operating Expense -----
Unusual Expense --9.04M29.74M-
EBIT after Unusual Expense --(9.04M)(90.96M)-
Non Operating Income/Expense ----193,000
Non-Operating Interest Income 188,000235,000539,0002.1M7.54M
Equity in Affiliates (Pretax) -----
Interest Expense ----3,000
Gross Interest Expense ----3,000
Interest Capitalized -----
Pretax Income (62.84M)(59.51M)(60.2M)(88.85M)(120.46M)
Income Tax -----
Income Tax - Current Domestic -----
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (62.84M)(59.51M)(60.2M)(88.85M)(120.46M)
Minority Interest Expense -----
Net Income (62.84M)(59.51M)(60.2M)(88.85M)(120.46M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (62.84M)(59.51M)(60.2M)(88.85M)(120.46M)
Preferred Dividends --20.09M--
Net Income Available to Common (62.84M)(59.51M)(80.29M)(88.85M)(120.46M)
EPS (Basic) (3.09)(2.87)(3.66)(1.60)(1.76)
Basic Shares Outstanding 20.32M20.72M21.92M55.62M68.43M
EPS (Diluted) (3.09)(2.87)(3.66)(1.60)(1.76)
Diluted Shares Outstanding 20.32M20.72M21.92M55.62M68.43M
EBITDA (62.3M)(58.91M)(50.92M)(60.45M)(126.93M)
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.